Ceryx Medical launches Cysoni bionic device for respiratory sinus arrhythmia


A collaboration between Ceryx Medical Limited and the scientists at the Auckland Bioengineering Institute (ABI) and the Universities of Bath and Bristol, have developed technology that they claim, could improve the outlook for patients with serious heart conditions.

Ceryx Medical bionic device
Ceryx Medical bionic device

Ceryx Medical’s Cysoni is a bionic device that paces the heart with real-time respiratory modulation, according to a press release. The research team claim that respiratory sinus arrhythmia (RSA) pacing increased cardiac output by 20%, compared to monotonic pacing. The press release highlights that the researchers claim this increase in output has led to a significant decrease in heart-failure-associated symptoms, such as apnoea. It is also noted the device has resulted in improvements in physical exercise. It is noted that the Cysoni device replicates RSA, triggering heartbeats based on respiratory function. According to the press release, pre-clinical data demonstrating an improvement in recorded cardiac output in heart failure is now published in Basic Research in Cardiology

Ceryx Medical was co-founded by Julian Paton, (professor of Translational Physiology, Auckland Bioengineering Institute, Auckland, New Zealand) and Professor Alain Nogaret (professor of Condensed Matter Physics at Bath, Bath, UK), with Stuart Plant (Chief Executive Officer, Ceryx Medical) as CEO.

The press release states, of the 26 million heart failure patients worldwide, around 50% die within five years of diagnosis. Stuart Plant believes that Cysoni stands to dramatically improve not just the existing health and wellbeing of cardiology patients, but also their prognoses. Plant explained “We are seeing, at the single heart cell level, repair to the structure of that cell because of the reinstatement of RSA via Cysoni. It is a huge scientific breakthrough. The improvement in the function of the heart combined with the repair of the heart muscle stands to dramatically improve therapy for patients with cardiac diseases such as heart failure. And while cardiology remains our firm focus, for the time being, we anticipate our technology being used to treat conditions including hypertension and spinal cord injuries, and even dementia.”

The first clinical study involving the Cysoni technology will begin later this year involving patients from hospitals in the UK, Australia, and New Zealand.


Please enter your comment!
Please enter your name here